source
- Boehringer Ingelheim to invest up to $1B in AI-driven solid tumor partnership with EnvisagenicsBoehringer Ingelheim announced a partnership with Envisagenics to develop precision oncology therapies that use artificial intelligence to identify cancer-specific RNA splicing alterations. The co…
- Roche presents positive Phase 2 results for enicepatide in overweight and obese type 2 diabetes patientsRoche has released new data from a Phase 2 trial of enicepatide, a peptide acquired from Carmot Therapeutics, focusing on overweight or obese adults with type 2 diabetes. The trial met its primary…